|
Protein
|
Primary tumors
|
Metastatic tumors
|
Sign test, P value
|
|---|
| |
0
|
1
|
2
|
0
|
1
|
2
| |
|---|
|
pHER1
|
25
|
--
|
5
|
11
|
--
|
19
|
0.0003
|
|
pHER2
|
17
|
5
|
7
|
14
|
10
|
6
|
0.6072
|
|
pHER3
|
23
|
--
|
5
|
16
|
--
|
13
|
0.0034
|
|
Nuclear pHER3
|
27
|
--
|
1
|
15
|
--
|
14
|
0.0002
|
|
HER4
|
--
|
13
|
17
|
--
|
19
|
10
|
0.1435
|
|
Cytoplasmic pErk
|
10
|
4
|
15
|
6
|
12
|
12
|
1.0000
|
|
Nuclear pErk
|
10
|
3
|
16
|
6
|
6
|
18
|
0.4545
|
|
Cytoplasmic pAkt
|
3
|
19
|
8
|
10
|
5
|
14
|
0.8036
|
|
Nuclear pAkt
|
16
|
8
|
8
|
10
|
7
|
12
|
0.0768
|
- Category 0 = number of negative cases, category 1 = number of weak-expressing (pHER2), low-expressing (HER4) or moderate-expressing (pErk and pAkt) cases, and category 2 = number of positive (pHER1 and pHER3) or strong-expressing (pHER2, pErk and pAkt) cases. Expression of pHER1, pHER3 and nuclear pHER3 was analyzed as negative or positive, hence '--' in category 1. HER4 expression was evaluated as either low or high, hence '--' in category 0. The Sign test was used to examine for significant differences in protein expression levels between primary and metastatic tumors. Bold data represent significant values.
